Affymetrix Vows that 2012 Will be 'Turnaround Year' after Q4 2011 Revenues Slide 23 Percent | GenomeWeb

This article was originally posted on Feb. 10.

By Justin Petrone

After a 'challenging' year of revenue decline, Affymetrix executives last week promised to return their company to growth, hoping that new products, such as the CytoScan HD array for cytogenetics research, will offset an anticipated drop in expression array sales.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."